Main Menu

Publications

Dr Anna Minchom

Publications Highlights View all by category

Types of Publications


Journal Articles

Coker, E.A. Stewart, A. Ozer, B. Minchom, A. Pickard, L. Ruddle, R. Carreira, S. Popat, S. O'Brien, M. Raynaud, F. de Bono, J. Al-Lazikani, B. Banerji, U. (2022). Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes. Mol cancer ther, Vol.21 (6), pp. 1020-1029.  show abstract

Cui, W. Milner-Watts, C. O'Sullivan, H. Lyons, H. Minchom, A. Bhosle, J. Davidson, M. Yousaf, N. Scott, S. Faull, I. Kushnir, M. Nagy, R. O'Brien, M. Popat, S. (2022). Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. , Vol.171, pp. 44-54.  show abstract

Castagnoli, F. Doran, S. Lunn, J. Minchom, A. O'Brien, M. Popat, S. Messiou, C. Koh, D.-. (2022). Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. , Vol.17 (7), p. e0270950.  show abstract

Lai-Kwon, J. Vanderbeek, A.M. Minchom, A. Lee Aiyegbusi, O. Ogunleye, D. Stephens, R. Calvert, M. Yap, C. (2022). Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum. , Vol.27 (9), pp. 768-777.  show abstract

Stapleton, S.E. Darlington, A.-. Minchom, A. Pal, A. Raynaud, F. Wiseman, T. (2022). Assessing cognitive toxicity in early phase trials - What are we missing?. Psychooncology, Vol.31 (3), pp. 405-415.  show abstract

Minchom, A. Viteri, S. Bazhenova, L. Gadgeel, S.M. Ou, S.-. Trigo, J. Bauml, J.M. Backenroth, D. Bhattacharya, A. Li, T. Mahadevia, P. Girard, N. (2022). Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung cancer, Vol.168, pp. 74-82.

Banerjee, S. Michalarea, V. Ang, J.E. Ingles Garces, A. Biondo, A. Funingana, I.-. Little, M. Ruddle, R. Raynaud, F. Riisnaes, R. Gurel, B. Chua, S. Tunariu, N. Porter, J.C. Prout, T. Parmar, M. Zachariou, A. Turner, A. Jenkins, B. McIntosh, S. Ainscow, E. Minchom, A. Lopez, J. de Bono, J. Jones, R. Hall, E. Cook, N. Basu, B. Banerji, U. (2022). A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer. , , pp. CCR-22.  show abstract

Cui, W. Milner-Watts, C. McVeigh, T.P. Minchom, A. Bholse, J. Davidson, M. Yousaf, N. MacMahon, S. Mugalaasi, H. Gunapala, R. Lee, R. George, A. Popat, S. O'Brien, M. (2022). A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. Lung cancer (amsterdam, netherlands), Vol.165, pp. 34-42.  show abstract

Tiu, C. Shinde, R. Pal, A. Biondo, A. Lee, A. Tunariu, N. Jhanji, S. Grover, V. Tatham, K. Gruber, P. Banerji, U. De Bono, J.S. Nicholson, E. Minchom, A.R. Lopez, J.S. (2021). A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy. , Vol.4 (4), pp. 189-195.  show abstract

Lai-Kwon, J. Tiu, C. Pal, A. Khurana, S. Minchom, A. (2021). Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. Critical reviews in oncology/hematology, Vol.159, pp. 103225-103225.

Joshi, K. Muhith, A. Obeid, M. Milner-Watts, C. Yousaf, N. Popat, S. Davidson, M. Bhosle, J. O’Brien, M. Minchom, A. (2021). Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung cancer, Vol.156, pp. 147-150.

Virtakoivu, R. Rannikko, J.H. Viitala, M. Vaura, F. Takeda, A. Lönnberg, T. Koivunen, J. Jaakkola, P. Pasanen, A. Shetty, S. de Jonge, M.J. Robbrecht, D. Ma, Y.T. Skyttä, T. Minchom, A. Jalkanen, S. Karvonen, M.K. Mandelin, J. Bono, P. Hollmén, M. (2021). Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical cancer research : an official journal of the american association for cancer research, Vol.27 (15), pp. 4205-4220.  show abstract

Manickavasagar, T. Yuan, W. Carreira, S. Gurel, B. Miranda, S. Ferreira, A. Crespo, M. Riisnaes, R. Baker, C. O'Brien, M. Bhosle, J. Popat, S. Banerji, U. Lopez, J. de Bono, J. Minchom, A. (2021). HER3 expression and MEK activation in non-small-cell lung carcinoma. Lung cancer management, , pp. ?-? (12).

Biondo, A. Pal, A. Riisnaes, R. Shinde, R. Tiu, C. Lockie, F. Baker, C. Bertan, C. Crespo, M. Ferreira, A. Pereira, R. Figueiredo, I. Miranda, S. Gurel, B. Carreira, S. Banerji, U. de Bono, J. Lopez, J. Tunariu, N. Minchom, A. (2021). Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience. Cancer treatment and research communications, Vol.27, pp. 100309-?.  show abstract

Lai-Kwon, J. Yin, Z. Minchom, A. Yap, C. (2021). Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials gov. Cancer med, Vol.10 (22), pp. 7943-7957.  show abstract

Bazhenova, L. Minchom, A. Viteri, S. Bauml, J.M. Ou, S.-. Gadgeel, S.M. Trigo, J.M. Backenroth, D. Li, T. Londhe, A. Mahadevia, P. Girard, N. (2021). Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung cancer, Vol.162, pp. 154-161.

Minchom, A. Tan, A.C. Massarelli, E. Subbiah, V. Boni, V. Robinson, B. Wirth, L.J. Hess, L.M. Jen, M. Kherani, J. Olek, E. McCoach, C.E. (2021). Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion‐Positive Non‐small Cell Lung Cancer in the Phase 1/2 LIBRETTO ‐001 Trial. The oncologist, .

Minchom, A. Yuan, W. Crespo, M. Gurel, B. Figueiredo, I. Wotherspoon, A. Miranda, S. Riisnaes, R. Ferreira, A. Bertan, C. Pereira, R. Clarke, M. Baker, C. Ang, J.E. Fotiadis, N. Tunariu, N. Carreira, S. Popat, S. O'Brien, M. Banerji, U. de Bono, J. Lopez, J. (2020). Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. Journal for immunotherapy of cancer, Vol.8 (1).  show abstract

Page, S. Milner-Watts, C. Perna, M. Janzic, U. Vidal, N. Kaudeer, N. Ahmed, M. McDonald, F. Locke, I. Minchom, A. Bhosle, J. Welsh, L. O'Brien, M. (2020). Systemic treatment of brain metastases in non-small cell lung cancer. European journal of cancer, Vol.132, pp. 187-198.

Tiu, C. Shinde, R. Yap, C. Rao Baikady, B. Banerji, U. Minchom, A.R. de Bono, J.S. Lopez, J.S. (2020). A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. The lancet. oncology, Vol.21 (7), pp. 889-891.

Collins, D.C. Sundar, R. Constantidinou, A. Dolling, D. Yap, T.A. Popat, S. O'Brien, M.E. Banerji, U. de Bono, J.S. Lopez, J.S. Tunariu, N. Minchom, A. (2020). Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. Bmc cancer, Vol.20 (1), pp. 1210-?.  show abstract

Terbuch, A. Tiu, C. Candilejo, I.M. Scaranti, M. Curcean, A. Bar, D. Estevez Timon, M. Ameratunga, M. Ang, J.E. Ratoff, J. Minchom, A.R. Banerji, U. de Bono, J.S. Tunariu, N. Lopez, J.S. (2020). Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. Clinical cancer research : an official journal of the american association for cancer research, Vol.26 (18), pp. 4805-4813.  show abstract

Guo, C. Chénard-Poirier, M. Roda, D. de Miguel, M. Harris, S.J. Candilejo, I.M. Sriskandarajah, P. Xu, W. Scaranti, M. Constantinidou, A. King, J. Parmar, M. Turner, A.J. Carreira, S. Riisnaes, R. Finneran, L. Hall, E. Ishikawa, Y. Nakai, K. Tunariu, N. Basu, B. Kaiser, M. Lopez, J.S. Minchom, A. de Bono, J.S. Banerji, U. (2020). Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet oncol, Vol.21 (11), pp. 1478-1488.  show abstract

Cojocaru, E. Scaranti, M. Minchom, A. (2019). Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. Journal of immunotherapy and precision oncology, Vol.2 (2), pp. 23-35.  show abstract

Moss, C.A. Cojocaru, E. Hanwell, J. Ward, S. Xu, W. van Zyl, M. O'Leary, L. de Bono, J.S. Banerji, U. Kaye, S.B. Minchom, A. George, A.J. Lopez, J. McVeigh, T.P. (2019). Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services. European journal of cancer (oxford, england : 1990), Vol.114, pp. 97-106.  show abstract

Georgiou, A. Minchom, A. O'Brien, M. (2019). Comment on ‘Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer’—No support for de-escalation of immunotherapy. European journal of cancer, Vol.115, pp. 24-26.

Stewart, A. Coker, E.A. Pölsterl, S. Georgiou, A. Minchom, A.R. Carreira, S. Cunningham, D. O'Brien, M.E. Raynaud, F.I. de Bono, J.S. Al-Lazikani, B. Banerji, U. (2019). Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. Molecular cancer therapeutics, Vol.18 (8), pp. 1396-1404.  show abstract

Mak, D.W. Li, S. Minchom, A. (2019). Challenging the recalcitrant disease—developing molecularly driven treatments for small cell lung cancer. European journal of cancer, Vol.119, pp. 132-150.

Georgiou, A. Khakoo, S. Edwards, P. Minchom, A. Kouvelakis, K. Kalaitzaki, E. Nobar, N. Calamai, V. Ifijen, M. Husson, O. Watkins, D. Rao, S. Chau, I. Cunningham, D. Starling, N. (2019). Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. Cancers (basel), Vol.11 (10).  show abstract

Minchom, A. Aversa, C. Lopez, J. (2018). Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Therapeutic advances in medical oncology, Vol.10, pp. 1758835918786658-?.  show abstract

Minchom, A. Thavasu, P. Ahmad, Z. Stewart, A. Georgiou, A. O'Brien, M.E. Popat, S. Bhosle, J. Yap, T.A. de Bono, J. Banerji, U. (2017). A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. Plos one, Vol.12 (10), p. e0186106.  show abstract

Puglisi, M. Stewart, A. Thavasu, P. Frow, M. Carreira, S. Minchom, A. Punwani, R. Bhosle, J. Popat, S. Ratoff, J. de Bono, J. Yap, T.A. O''Brien, M. Banerji, U. (2016). Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. Oncology, Vol.90 (5), pp. 280-288.  show abstract

Kumar, R. Lu, S.K. Minchom, A. Sharp, A. Davidson, M. Gunapala, R. Yap, T.A. Bhosle, J. Popat, S. O’Brien, M.E. (2016). A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer chemotherapy and pharmacology, Vol.77 (2), pp. 375-383.

Minchom, A. Punwani, R. Filshie, J. Bhosle, J. Nimako, K. Myerson, J. Gunapala, R. Popat, S. O'Brien, M.E. (2016). A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. European journal of cancer, Vol.61, pp. 102-110.

Minchom, A. Yu, K.C. Bhosle, J. O'Brien, M. (2014). The diagnosis and treatment of brain metastases in EGFR mutant lung cancer. Cns oncology, Vol.3 (3), pp. 209-217.  show abstract

Minchom, A.R. Saksornchai, K. Bhosle, J. Gunapala, R. Puglisi, M. Lu, S.K. Nimako, K. Coward, J. Yu, K.C. Bordi, P. Popat, S. O'Brien, M.E. (2014). An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity. Bmj open respiratory research, Vol.1 (1), pp. e000061-e000061.

Young, K. Minchom, A. Larkin, J. (2012). BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAFV600E mutation. Future oncology, Vol.8 (5), pp. 499-507.  show abstract

Minchom, A. Young, K. Larkin, J. (2011). Ipilimumab: showing survival benefit in metastatic melanoma. Future oncology, Vol.7 (11), pp. 1255-1264.  show abstract

Minchom, A. Chan, S. Melia, W. Shah, R. (2010). An Unusual Case of Pancreatic Cancer with Leptomeningeal Infiltration. Journal of gastrointestinal cancer, Vol.41 (2), pp. 107-109.

Minchom, A. Jones, R.L. Fisher, C. Al-Muderis, O. Ashley, S. Scurr, M. Karavasilis, V. Judson, I.R. (2010). Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma. Sarcoma, Vol.2010, pp. 1-8.  show abstract

Bowcock, S.J. Minchom, A. Yates, L.R. Ryali, M.M. (2008). Ultra low dose thalidomide in elderly patients with myeloma. British journal of haematology, Vol.141 (1), pp. 120-122.

Minchom, A. Mak, D. Gunapala, R. Walder, D. Kumar, R. Yousaf, N. Hodgkiss, A. Bhosle, J. Popat, S. O'Brien, M.E. A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma. Plos one, Vol.14 (11), pp. e0225509-?.  show abstract

Pal, A. Stapleton, S. Yap, C. Lai-Kwon, J. Daly, R. Magkos, D. Baikady, B.R. Minchom, A. Banerji, U. De Bono, J. Karikios, D. Boyle, F. Lopez, J. Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT). Bmj open, Vol.11 (9), pp. e049217-e049217.  show abstract

Hindocha, S. Campbell, D. Ahmed, M. Giorgakoudi, K. Sharma, B. Yousaf, N. Molyneaux, P. Hunter, B. Kalsi, H. Cui, W. Davidson, M. Bhosle, J. Minchom, A. Locke, I. McDonald, F. O'Brien, M. Popat, S. Lee, R.W. Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications. Frontiers in medicine, Vol.8, pp. 764563-?.  show abstract

Curcean, S. Cheng, L. Picchia, S. Tunariu, N. Collins, D. Blackledge, M. Popat, S. O'Brien, M. Minchom, A. Leach, M.O. Koh, D.-. Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations. Jto clinical and research reports, Vol.2 (12), pp. 100253-?.  show abstract

Yap, C. A Phase 1, Dose Escalation Study of Guadecitabine (SGI-110) in Combination with Pembrolizumab in Patients with Solid Tumours. Journal for immunotherapy of cancer, .


Conferences

Hamilton, E.P.Shapiro, C.L.Boni, V.Martin Jimenez, M.Del Conte, G.Cortés, J.Agrawal, L.Arkenau, H.-.Tan, A.R.Debruyne, P.R.Minchom, A.R.Rutten, A.Valdes-Albini, F.Yu, E.Suto, F.Cheng, F.-.Augustine, B.Cheng, B.Barrios, D.Hurvitz, S.A. (2022). 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer, Annals of Oncology, Vol.33, p.S196.

Girard, N.Minchom, A.Ou, S.-.Gadgeel, S.M.Trigo, J.Viteri, S.Bauml, J.M.Londhe, A.Mahadevia, P.Bazhenova, L. (2022). Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors, Clinical Lung Cancer, .

Viteri, S.Bauml, J.M.Bazhenova, L.Ou, S.-.Girard, N.Schaffer, M.Rose, J.Curtin, J.Karkera, J.Mahadevia, P.Minchom, A.R. (2021). Real-world frequency of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations by site of insertion, JOURNAL OF THORACIC ONCOLOGY, Vol.16 (4), pp.S699-1.

Bauml, J.M.Viteri, S.Minchom, A.Bazhenova, L.Ou, S.Schaffer, M.Le Croy, N.Riley, R.Mahadevia, P.Girard, N. (2021). Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real-World Datasets, JOURNAL OF THORACIC ONCOLOGY, Vol.16 (3), pp.S208-2.

Girard, N.Bazhenova, L.Minchom, A.Ou, S.Gadgeel, S.Trigo, J.Viteri, S.Li, G.Mahadevia, P.Londhe, A.Backenroth, D.Li, T.Bauml, J.M. (2021). Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations, JOURNAL OF THORACIC ONCOLOGY, Vol.16 (3), pp.S145-2.

Hamilton, E.Shapiro, C.L.Petrylak, D.Boni, V.Martin, M.Del Conte, G.Cortes, J.Agarwal, L.Arkenau, H.-.Tan, A.R.Debruyne, P.Minchom, A.Rutten, A.Valdes-Albini, F.Yu, E.Y.Augustine, B.D'Amelio, A.Barrios, D.Hurvitz, S.A. (2021). Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study, CANCER RESEARCH, Vol.81 (4), p. 1.

Spira, A.Krebs, M.Cho, B.C.Besse, B.Goldman, J.Janne, P.Lee, C.K.Ma, Z.Mansfield, A.Minchom, A.Ou, S.Salgia, R.Wang, Z.Gao, G.Curtin, J.Roshak, A.Schnepp, R.Thayu, M.Knoblauch, R.Trigo, J.M. (2021). Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS, JOURNAL OF THORACIC ONCOLOGY, Vol.16 (10), pp.S874-2.

Hollmen, M.Virtakoivu, R.Jaakkola, P.Minchom, A.Jalkanen, S.Karvonen, M.Mandelin, J.Koivunen, J.Bono, P. (2019). Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours, Presented at Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), SWITZERLAND, Geneva. ANNALS OF ONCOLOGY, Vol.30, p.1.

Minchom, A.Gunapala, R.Walder, D.Kumar, R.Bhosle, J.Popat, S.Yousaf, N.O’Brien, M. (2017). P1.03-029 Study of Plasma Homocysteine as a Marker of Toxicity and Depression in Patients Treated with Pemetrexed-Based Chemotherapy, Journal of Thoracic Oncology, Vol.12 (11), p.S1962.

Minchom, A.R.Punwani, R.Filshie, J.Bhosle, J.Nimako, K.Gunapala, R.Popat, S.O'Brien, M.E. (2016). 163 A randomised study comparing the effectiveness of acupuncture (A) or morphine (M) versus the combination (AM) for the relief of dyspnoea in patients with advanced non small cell lung cancer and mesothelioma, Lung Cancer, Vol.91, p.S59.

O'Brien, M.E.Minchom, A.R.Punwani, R.Bhosle, J.Nimako, K.Gunapala, R.Popat, S.Filshie, J. (2015). Randomised Study of Acupuncture, Morphine and Combination in NSCLC/Mesothelioma, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S366-S367.

Kumar, R.Lo, K.Minchom, A.R.Sharp, A.Davidson, M.Gunapala, R.Yap, T.Bhosle, J.Popat, S.O'Brien, M.E. (2015). A Phase 1b Trial of the Combination of Capecitabine and Erlotinib in Advanced Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S547-S548.

In this section

Publications